Document Detail

A study on inhibition mechanism of breast cancer cells by bis-type triaziquone.
MedLine Citation:
PMID:  20371239     Owner:  NLM     Status:  MEDLINE    
The objectives of this study were to evaluate the antiproliferation effect of a synthetic quinone-containing compound bis-type triaziquone (BTZQ) on breast cancer cells BC-M1 and MCF-7. At a dose of 0.42 and 0.79 microM, BTZQ showed a 50% inhibition on BC-M1 and MCF-7 cell growth after 24 h treatment, respectively, but reduced to 0.2 and 0.61 microM after 48 h. A low toxic effect was observed for skin fibroblast cell after BTZQ treatment for 48 h at a dose from 0.0625-0.25 microM. BTZQ was more effective in inhibiting growth of breast cancer cells than tamoxifen. Additionally, BTZQ-treated BC-M1 cells under hypoxia condition for 48 h exhibited a higher cytotoxicity than under aerobic condition. Cell cycle analysis revealed the arrest of BC-M1 cells at G2/M phase, with accumulation of apoptotic cells at the sub-G1 phase being enhanced following a rise in dose. The expression levels of caspase-3, caspase-8 and caspase-9 were elevated in both dose- and time-dependent responses. Western blot analysis indicated that BTZQ may up-regulate expression of cyclin B, p21, p53 and cytochrome c, but down-regulate cdk1 expression in a dose-dependent manner, leading to apoptosis of BC-M1 cells. All these results suggested that BTZQ may be a potential anti-breast cancer drug.
Yuh-Ling Lin; Yi-Ting Su; Bing-Huei Chen
Related Documents :
18715689 - Establishment and characterization of a new human acute myelocytic leukemia cell line s...
8552379 - Adenovirus-mediated p16/cdkn2 gene transfer induces growth arrest and modifies the tran...
9067289 - P53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation.
12488329 - P53 is required for 1,25-dihydroxyvitamin d3-induced g0 arrest but is not required for ...
18789159 - Gadd45 in stress signaling.
12826669 - Hyperproliferation and p53 status of lens epithelial cells derived from alphab-crystall...
9050809 - Epidermal aminopeptidase activity and metabolism as observed in an organized hacat cell...
8890159 - Underexpression of the 43 kda inositol polyphosphate 5-phosphatase is associated with c...
17050169 - The contribution of dna repair and antioxidants in determining cell type-specific resis...
Publication Detail:
Type:  Journal Article     Date:  2010-04-02
Journal Detail:
Title:  European journal of pharmacology     Volume:  637     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1-10     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier B.V. All rights reserved.
School of Medicine, Fu Jen University, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Alkylating / pharmacology*
Apoptosis / drug effects
Blotting, Western
Breast Neoplasms / enzymology,  pathology*
Caspase 3 / metabolism
Caspase 8 / metabolism
Caspase 9 / metabolism
Cell Division / drug effects
Cell Line, Tumor
Dose-Response Relationship, Drug
G2 Phase / drug effects
Time Factors
Triaziquone / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 68-76-8/Triaziquone; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reactive oxygen species and endothelial function in diabetes.
Next Document:  Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.